Protective Effect of PPT and Ginsenoside-Re in MPP+-treated SH-SY5Y Cells

Abstract

Abstract: Objective:To investigate the protective effect of PPT (protopanaxatriol group) and ginsenoside-Re on 1-methyl-4-phenylpyridinium ion (MPP+)-induced damage in SH-SY5Y（human dopaminergic neuroblastoma cell line）cells. Methods: SH-SY5Y cells were treated with different concentrations of PPT, ginsenoside-Re or MPP+ containing serum. MTT colorimetry was used to test the viability of the cells and the survival rates were calculated and analyzed. Results: Cells treated by either 5 µmol•L-1, 10 µmol•L-1 PPT or ginsenoside-Reshowed significantly higher viability as compared to control group (P<0.05). In addition, 10% PPT treated or ginsenoside-Remedicated serum treated groups showed similar protective effect. Conclusion: PPT and ginsenoside-Re have neuroprotective effects in a cell model of Parkinson’s disease MPP⁺-induced SH-SY5Y cell death, suggesting that both PPT and ginsenoside-Re may have anti-PD effect.

Key words: protopanaxatriol group, ginsenoside-Re, SH-SY5Y cells, Parkinson&, rsquo, s disease, , neuroprotective effects

CLC Number:

R965

LI Dong-wei, DOU De-qiang. Protective Effect of PPT and Ginsenoside-Re in MPP⁺-treated SH-SY5Y Cells[J]. ACTA NEUROPHARMACOLOGICA, 2011, 1(5): 1-7.

References

[1]Steven Karceski. Parkinson disease and polyneuropathy[J]. Neurology, 2011, 77(22):e132-e134.

[2]Halliday GM, Del Tredici K, Braak H. Critical appraisal of brain pathology staging related to presymptomatic and symptomatic cases of sporadic Parkinson’s disease [J]. J Neural Transm (Suppl), 2006, 70: 99-103.

[3]Guo Hua, Song Junping. Latest research progress at home and abroad of pathogenesis of Parkinson’s disease[J]. Occupy and Health, 2012, 28(4):490-492.

[4] Symptomatic pharmacological therapy in Parkinson’s disease [M]//Royal College of Physicians. Parkinson’s disease: national clinical guideline for diagnosis and management in primary and secondary care. London: the Lavenham Press Ltd, Sudbury, Suffolk, 2006: 59-97.

[5] Mark R.Cookson. The biochemistry of Parkinson’s disease[J]. Annn Rev Biochem, 2005, 74:29-52.

[6]张登本．神农本草经卷二[M]//全注全译神农本草经．第一版．北京：新世界出版社，2009：17-18.

[7]吴崑著，宋白杨校注．中风门第一[M]//医方考脉语．第一版．北京：中国医药科技出版社，2012：10.

[8]危亦林著，金芬芳校注．卷第十三风科[M]//世医得效方．第一版．北京：中国医药科技出版社，2011：256-257.

[9]危亦林著，戴铭校注．卷第十三风科[M]//世医得效方．第二版．北京：中国医药科技出版社，2009：542.

[10] 孙一奎著，周琦校注. 赤水玄珠[M]//赤水玄珠．第一版．北京：中国医药科技出版社，2011：495.

[11] 解洪荣，张玉花，李雪松，等．MPTP/MPP+诱导的帕金森病实验模型的研究进展[J]．医学综述，2011，17（5）：669-672.

[12] Celine A. Beamer, David M. Shepherd .Inhibition of TLR ligand- and interferon gamma-induced murine microglial activation by Panax notoginseng[J].J Neuroimmune Pharmacol, 2012, 7(2):465-476.

[13] Zhang Xu, Yu Li, Bi Hong-tao, et al. Total fractionation and characterization of the water-soluble polysaccharides isolated from Panax ginseng C.A. Meyer[J]. Carbohydrate Polymer, 2009, 77(3):544-552.

[14] Wang Jun, Xu Hua-min, Yang Hai-dong, et al. Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins[J]. Neurochem Int, 2009, 54(1):43-48.

[15] Chen Li-min, Zhou Xiao-mian, Cao Ying-lin, et al. Neuroprotection of ginsenoside Re in cerebral ischemia-reperfusion injury in rats[J]. J Asian Nat Prod Res, 2008, 10 (5-6):439-445.

[16] Xu Bei-Bei, He Wen-fei, Lu Jin-cai, et al. Effects of ginsenoside Re on the levels of brain monoamines transmitters and serum corticosterone in water immersion-restraint rats[J].Natural product research development, 2009, 21(5):752-756, 786.

[17] Liu Qian, Kou Jun-ping, Yu Bo-yang. Ginsenoside Rg1 protects against hydrogen peroxide-induced cell death in PC12 cells via inhibiting NF-κB activation[J]. Neurochem Int, 2011,58(1):119-125.

[18] Hu Sheng-quan, Han Ren-wen, Shinghung Mak, et al. Protection against 1-methyl-4-phenylpyridinium ion (MPP+)-induced apoptosis by water extract of ginseng (Panax ginseng C.A. Meyer) in SH-SY5Y cells[J].J Ethnopharmacol, 2011, 135(1):34-42.

Protective Effect of PPT and Ginsenoside-Re in MPP⁺-treated SH-SY5Y Cells

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

[1]	XIE bin, HUANG Zhi-yuan, LIN Duo-duo, YANG Fu-long, XIE Yi-bin. Effect of Acupuncture Combined with Medicine on Depressive Symptoms of Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 5-8.
[2]	SUN Li-cong, ZHANG Dan-shen. Research Progress on Potential Treatment of Alzheimer’s Disease with Alkaloids [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 33-37.
[3]	WANG Si-yi, LI Xian-xiang, LIU Yi-zhou, DU Shuang, GE Chao, LIU Si-si. Current Situation and Prospect of Alzeimer’s Disease Treatment [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 38-42.
[4]	ZHAO Yu-wei, ZHEN Yan-jie, DAI Yue-ying, SHEN Li-xia. Study on the Neuroprotective Mechanism of Quercetin in Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(5): 55-64.
[5]	HAI Ji-tao, LUO Huan-min. Progress on the Relationship between Pathogenic Microorganisms and Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(4): 58-64.
[6]	ZHANG Hao-ting, SONG Gui-qin, CUI Ruo-tong, HAO Min, WANG Wen-dong. Mining Target Genes of Alzheimer’s Disease Associated with Biological Clock by Bioinformatics Analysis [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 1-7.
[7]	GAO Yun-xia, ZHANG Yuan-yuan. The Role of Endoplasmic Reticulum Stress in Senile Macular Degeneration [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 21-26.
[8]	YANG Xu-hua, DU Shuang, SHEN Li-xia, HAO Jun-rong. Research Progress in Drug Treatment of Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(3): 47-53.
[9]	MO Cui-ying, LUO Guo-ping. Influence of Nimergoline Combined with Trasylin and Psychotherapy for Depression in Patients with Post-stroke Depression [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(2): 7-10.
[10]	LIU Shan, LI Wei. Research Progress on Pharmacological Effects of L-theanine [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(2): 24-32.
[11]	ZHEN Yan-jie, GUO Tong-lin, ZHAO Yu-wei, SHEN Li-xia. Study Progress on Phytoestrogen-Mediated Mitochondrial Pathway’s Neuroprotective Effects in Alzheimer’s Disease [J]. ACTA NEUROPHARMACOLOGICA, 2020, 10(1): 40-46.
[12]	YANG-Lin，AI-Jing. Research Progress of Brain-Derived Estrogen in Alzheimer’s Disease [J]. Acta Neuropharmacologica, 2019, 9(5): 50-64.
[13]	ZHANG Shuai，AI Jing. Glutamate Dysfunction and Alzheimer’s Disease [J]. Acta Neuropharmacologica, 2018, 8(6): 9-20.
[14]	王奇. Bushen-Yizhi Formula Inhibits the NLRP3/NFκB Mediated Neuroinflammation and Improves the Motor Dysfunction in a Mouse Model of Parkinson's Disease [J]. Acta Neuropharmacologica, 2018, 8(5): 71-72.
[15]	CUI Su-ying, SONG Jin-zhi, CUI Xiang-yu, HU Xiao, DING Hui, YE Hui, ZHANG Yong-he. Intracerebroventricular Streptozocin-induced Alzheimer’s Disease-like Sleep Disorders: Role of the GABAergic System in the Parabrachial Complex [J]. Acta Neuropharmacologica, 2018, 8(5): 96-97.